(GALD) Galderma N - Ratings and Ratios

Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: (N/A)

Injectables, Skincare, Treatments

GALD EPS (Earnings per Share)

EPS (Earnings per Share) of GALD over the last years for every Quarter: "2023-03": 0.01, "2023-06": 0.02, "2023-12": -0.23, "2024-03": 0.09, "2024-06": 0.09, "2024-12": 0.67,

GALD Revenue

Revenue of GALD over the last years for every Quarter: 2023-03: 921.64085, 2023-06: 1826.840062, 2023-12: 1840.388324, 2024-03: 999.28304, 2024-06: 995.34964, 2024-12: 1925.123175,

Description: GALD Galderma N

Galderma Group AG is a global dermatology company that has established a strong presence in the market with its comprehensive portfolio of science-backed brands and services. The companys diversified offerings cater to various segments of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology, making it a one-stop solution for patients and healthcare professionals alike.

The companys flagship brands, such as Dysport/Azzalure, Restylane, and Sculptra, have gained significant traction in the injectable aesthetics market, while Cetaphil and Alastin have become household names in dermatological skincare. Additionally, Galdermas therapeutic dermatology portfolio includes a range of products, such as Soolantra, Epiduo, and Differin, which are used to treat various skin conditions. With a history dating back to 1981, the company has developed a strong expertise in dermatology and has established itself as a leader in the industry.

From a technical analysis perspective, Galdermas stock has shown a strong upward trend, with the short-term and long-term moving averages indicating a bullish signal. The stocks relative strength index (not provided) and the current price above the SMA20 and SMA50 suggest a positive momentum. Using the provided technical data, we can forecast that the stock may continue its upward trend, potentially reaching a price of 125-130 CHF in the near term, based on the current ATR and the stocks historical volatility.

Fundamentally, Galdermas market capitalization stands at approximately 24.3 billion CHF, with a P/E ratio of 126.54, indicating a relatively high valuation. However, the forward P/E ratio of 45.45 suggests that the companys earnings are expected to grow significantly in the future. With a return on equity (RoE) of 2.28%, the companys profitability is relatively low, but this may be attributed to the high R&D expenses associated with developing new products and treatments. Using the provided fundamental data, we can forecast that Galdermas stock may continue to perform well, driven by the companys strong portfolio of products and its expected earnings growth, potentially leading to a re-rating of the stocks valuation.

Combining both technical and fundamental analysis, we can conclude that Galderma Group AG is a well-positioned company in the dermatology market, with a strong portfolio of products and a growing presence in the industry. While the stocks valuation is relatively high, the companys expected earnings growth and strong technical momentum suggest that the stock may continue to perform well in the near term, potentially reaching a price of 130-140 CHF.

Additional Sources for GALD Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

GALD Stock Overview

Market Cap in USD 35,263m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO / Inception

GALD Stock Ratings

Growth Rating 49.2
Fundamental 35.1
Dividend Rating 1.0
Rel. Strength 82.3
Analysts -
Fair Price Momentum 128.45 CHF
Fair Price DCF 34.63 CHF

GALD Dividends

Dividend Yield 12m 0.12%
Yield on Cost 5y 0.23%
Annual Growth 5y %
Payout Consistency 1.0%
Payout Ratio 27.3%

GALD Growth Ratios

Growth Correlation 3m 96.4%
Growth Correlation 12m 75.8%
Growth Correlation 5y 87.3%
CAGR 5y 96.62%
CAGR/Max DD 5y 2.49
Sharpe Ratio 12m 1.75
Alpha 62.38
Beta 0.709
Volatility 30.23%
Current Volume 354.1k
Average Volume 20d 324.2k
Stop Loss 121.9 (-3.5%)
What is the price of GALD shares?
As of July 10, 2025, the stock is trading at CHF 126.30 with a total of 354,148 shares traded.
Over the past week, the price has changed by +7.31%, over one month by +11.87%, over three months by +72.83% and over the past year by +73.28%.
Is Galderma N a good stock to buy?
Partly, yes. Based on ValueRay´s Fundamental Analyses, Galderma N (SW:GALD) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 35.12 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GALD is around 128.45 CHF . This means that GALD is currently overvalued and has a potential downside of 1.7%.
Is GALD a buy, sell or hold?
Galderma N has no consensus analysts rating.
What are the forecasts for GALD share price target?
According to our own proprietary Forecast Model, GALD Galderma N will be worth about 146.2 in July 2026. The stock is currently trading at 126.30. This means that the stock has a potential upside of +15.76%.
Issuer Target Up/Down from current
Wallstreet Target Price 110 -12.9%
Analysts Target Price - -
ValueRay Target Price 146.2 15.8%